已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis

芬戈莫德 S1PR1型 鞘氨醇-1-磷酸受体 1-磷酸鞘氨醇 鞘氨醇激酶 实验性自身免疫性脑脊髓炎 多发性硬化 鞘氨醇 药理学 免疫系统 医学 受体 功能选择性 免疫学 神经科学 生物 G蛋白偶联受体 癌症研究 内科学 血管内皮生长因子受体 血管内皮生长因子A 血管内皮生长因子
作者
Reshmi Roy,Alaa A Alotaibi,Mark S. Freedman
出处
期刊:CNS Drugs [Adis, Springer Healthcare]
卷期号:35 (4): 385-402 被引量:94
标识
DOI:10.1007/s40263-021-00798-w
摘要

Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral disease-modifying therapy (DMT) used for the treatment of the relapsing forms of multiple sclerosis (MS). Development of this new class of therapeutic compounds has continued to be a pharmacological goal of high interest in clinical trials for treatment of various autoimmune disorders, including MS. S1P is a physiologic signaling molecule that acts as a ligand for a group of cell surface receptors. S1PRs are expressed on various body tissues and regulate diverse physiological and pathological cellular responses involved in innate and adaptive immune, cardiovascular, and neurological functions. Subtype 1 of the S1PR (S1PR1) is expressed on the cell surface of lymphocytes, which are well known for their major role in MS pathogenesis and play an important regulatory role in the egress of lymphocytes from lymphoid organs to the lymphatic circulation. Thus, S1PR1-directed pharmacological interventions aim to modulate its role in immune cell trafficking through sequestration of autoreactive lymphocytes in the lymphoid organs to reduce their recirculation and subsequent infiltration into the central nervous system. Indeed, receptor subtype selectivity for S1PR1 is theoretically favored to minimize safety concerns related to interaction with other S1PR subtypes. Improved understanding of fingolimod's mechanism of action has provided strategies for the development of the more selective second-generation S1PR modulators. This selectivity serves to reduce the most important safety concern regarding cardiac-related side effects, such as bradycardia, which requires prolonged first-dose monitoring. It has led to the generation of smaller molecules with shorter half-lives, improved onset of action with no requirement for phosphorylation for activation, and preserved efficacy. The shorter half-lives of the second-generation agents allow for more rapid reversal of their pharmacological effects following treatment discontinuation. This may be beneficial in addressing further treatment-related complications in case of adverse events, managing serious or opportunistic infections such as progressive multifocal leukoencephalopathy, and eliminating the drug in pregnancies. In March 2019, a breakthrough in MS treatment was achieved with the FDA approval for the second S1PR modulator, siponimod (Mayzent), for both active secondary progressive MS and relapsing-remitting MS. This was the first oral DMT specifically approved for active forms of secondary progressive MS. Furthermore, ozanimod received FDA approval in March 2020 for treatment of relapsing forms of MS, followed by subsequent approvals from Health Canada and the European Commission. Other second-generation selective S1PR modulators that have been tested for MS, with statistically significant data from phase II and phase III clinical studies, include ponesimod (ACT-128800), ceralifimod (ONO-4641), and amiselimod (MT-1303). This review covers the available data about the mechanisms of action, pharmacodynamics and kinetics, efficacy, safety, and tolerability of the various S1PR modulators for patients with relapsing-remitting, secondary progressive, and, for fingolimod, primary progressive MS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1499yqq完成签到,获得积分10
1秒前
气球好饿完成签到,获得积分10
1秒前
ding的应助被俭朴灵竹采纳,获得10
1秒前
2秒前
优美松思完成签到,获得积分10
3秒前
5秒前
腼腆的初蓝完成签到,获得积分10
5秒前
6秒前
6秒前
6秒前
科研通AI6.4的应助被南歪歪采纳,获得30
6秒前
gentle发布了新的文献求助10
9秒前
9秒前
u605603发布了新的文献求助10
10秒前
无名氏完成签到,获得积分10
10秒前
11秒前
hayidaqing完成签到,获得积分10
13秒前
琉璃完成签到,获得积分10
14秒前
14秒前
heaven发布了新的文献求助10
14秒前
大个的应助被夏侯乌采纳,获得10
15秒前
15秒前
焱焱不忘完成签到 ,获得积分0
16秒前
情怀的应助被青阳子采纳,获得30
16秒前
浮云发布了新的文献求助10
16秒前
16秒前
17秒前
17秒前
姜锦令完成签到,获得积分20
18秒前
19秒前
妮妮完成签到 ,获得积分10
19秒前
DW的应助被古德猫宁采纳,获得10
20秒前
艾伦丶耶格尔完成签到,获得积分10
20秒前
自由哥完成签到,获得积分10
20秒前
姜锦令发布了新的文献求助10
22秒前
22秒前
yr发布了新的文献求助10
22秒前
喃喃完成签到 ,获得积分10
22秒前
诸葛明明的应助被wu采纳,获得10
23秒前
OK发布了新的文献求助10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184619
求助须知:如何正确求助?哪些是违规求助? 9573576
关于积分的说明 21832380
捐赠科研通 7781845
什么是DOI,文献DOI怎么找? 3434399
关于科研通互助平台的介绍 2558498
邀请新用户注册赠送积分活动 2481003